TechTalk Blog
GPhotospace Leverages Gmail to Create Firefox Add-On for Free Private Photo Sharing-Proceeds to Support Sustainability

GPhotospace.com announced today the launch of PC and Mac versions of the GPhotospace Add-on for Firefox and Flock. Leveraging the Gmail platform, the GPhotospace Add-on shares albums online many times faster than most solutions. GPhotospace also announced today that proceeds from the software will be donated to help sustainability in rural Africa through the relief organization Canadian Physicians for Aid and Relief.

Using GPhotospace, private photo sharing becomes extremely straightforward. In a seamless experience within the Add-on, users simply select their photos, upload them to their GMail storage, select their recipients and send album viewing invitations through email.

Says founder Colin How, "I was on my phone with my brother while he was getting started with GPhotospace. Within seconds he had selected 170 megs of images and was sharing them with me. The speed is the difference maker."

Addressing privacy concerns, GPhotospace has engineered a unique solution where users' Gmail credentials are used to log-in, but these credentials are never actually sent or stored on any servers other than Gmail's servers, using an encrypted https connection. Additionally, users who choose not to use their main Gmail account with GPhotospace can simply create a new Gmail account specifically for their photo storage.

"This is really the best of both worlds for those wanting quick private sharing," says GPhotospace CTO John Harley. "For Gmail users, the familiar interface will have them sharing photo albums in seconds. For those not using Gmail as their main email program, GPhotospace is a compelling reason to grab a free Gmail account and use it exclusively to share their photos, quickly and securely."

GPhotospace founders Colin How and John Harley are excited to give their user-base the ability to make a real difference in people's lives. In lieu of payment, they are asking those who rely on GPhotospace to make a donation to help plant a tree in Africa through CPAR (www.cpar.ca/youcanhelp.asp?page=planttree). "CPAR is very excited about the opportunity that this partnership with GPhotospace presents. We believe that this joint effort which links technology with eco-friendly sustainable solutions such as tree-planting in Africa, is an excellent way to support communities on a global scale," says Roxane Tracey, Communications & Fundraising Manager, CPAR.

GPhotospace is now available for immediate download for Mac and PC at http://www.gphotospace.com/download.html

About GPhotospace.com

GPhotospace was created by a group of photo enthusiasts and Internet veterans eager to break down the barriers of photo-sharing online. The result is a Firefox extension that leverages Gmail to provide quick, easy uploading with loads of free storage.

The GPhotospace team has over 30 years experience working in the digital imaging software space for companies such as Adobe and ACD Systems. The combination of industry knowledge and shared frustrations led to the creation of this new extension that facilitates online photo sharing among friends and family.

Learn more about GPhotospace or contact GPhotospace at http://www.gphotospace.com/

New Research Universities' Council Announced

The Presidents of the University of British Columbia, Simon Fraser University, the University of Victoria and the University of Northern British Columbia are pleased to announce the formation of the Research Universities’ Council of BC. RUCBC will provide a coordinated approach to the development of relevant public policy related to current and future issues facing the four research-intensive universities in British Columbia.

“The BC post-secondary system has undergone fundamental change over the last decade and as a result we think it is important that the issues facing our four research-intensive institutions be coordinated and thoughtfully considered.” said Council Chair and UBC President and Vice Chancellor Stephen Toope. “RUCBC will seek to enhance our capacity for excellence in research, expand opportunities for graduate students and improve the undergraduate teaching and learning experience. All are critical to the future sustainability of the BC economy.”

Don Avison has been appointed president of the Research Universities’ Council effective November 15th, 2008. “This is an exciting opportunity,” said Avison. “The four research-intensive universities in British Columbia are consistently recognized as national leaders and we look forward to building on those strengths.”

The Research Universities’ Council will also continue to work closely with other post-secondary institutions and in partnership with the Government of British Columbia in pursuit of enhanced opportunities for our students and a continuing commitment to excellence. According to Avison, “we all share the goal of building a stronger future for British Columbia.”

 

Media Contact:

The Research Universities’ Council of British Columbia
250-480-4839

LifeSciences British Columbia Recognizes Dr. Michael Hayden, Named Canada’s Health Researcher of the Year

November 19, 2008;  Vancouver, BC – LifeSciences BC is pleased to announce that one of British Columbia’s pre-eminent health researchers, Dr. Michael Hayden, Director and Senior Scientist at the Centre for Molecular Medicine and Therapeutics, and  University Killam Professor, Department of Medical Genetics at UBC has received the Canadian Institutes of Health Research’s (CIHR) Michael Smith Prize in Health Research:  Canada's Health Researcher of the Year award. Named in honor of the late Dr. Michael Smith, CIHR grants this prestigious award annually to a Canadian researcher in Biomedical and Clinical Research who has demonstrated outstanding commitment, innovation, creativity, achievement and leadership in health research.

“Clearly this is an accomplishment worthy of great celebration amongst our health research community and province as a whole,” commented Karimah Es Sabar, President, LifeSciences British Columbia.  “On behalf of this entire community, we applaud and thank Dr. Hayden for his outstanding work, and for bringing this recognition to BC. The contributions he has made to the health of patients while also the development of our biotech and life sciences industry here are immeasurable, thus extremely worthy of this honour, ” she noted.

British Columbia Minister of Health Services, the Honourable George Abbott added, “The late Dr. Michael Smith made British Columbia his home for more than 40 years, and left behind a great legacy as a scientist and humanitarian. I know all British Columbians will join me in congratulating Dr. Michael Hayden on receiving this award. We know that he and his team are building on this legacy, where world-class health research being conducted on Canada’s west coast is helping patients around the world.”

Throughout his career, Dr. Hayden has made major contributions to scientific excellence and to translating research findings into treatment approaches and services for patients.  Dr. Hayden nurtures a collaborative spirit and a supportive environment for investigators with varied expertise to work together towards a single mission:  building a healthier future. Dr. Hayden has also forged important linkages between researchers and industry, having founded multiple successful Canadian biotechnology companies in order to move research findings forward to therapeutic applications for the benefit of patients.  

As part of this distinction, Dr. Hayden will receive a research award of $500,000. During the next two years, he will use the award to support the operating costs for four new trainee awards in the areas of Global Health, Rare Diseases, Mental Health, and Biotechnology under the banner of Ripples of Hope. Dr. Hayden, a native of South Africa, has borrowed this term from a speech he attended when he was 15 years old, by Robert F. Kennedy in 1966 at the University of Cape Town. Dr. Hayden has already secured an additional $700,000 from a pharmaceutical partner that will go directly towards a related endowment, and he will continue working with the BC Children’s Hospital Foundation to raise additional funds to go directly towards this endowment or as annual trainee awards.

“Essentially what I’m hoping to do with these awards is create ripples of hope, that together with support from many others, will have impact against certain things we’re fighting against,” commented Dr. Hayden. “One such award will foster someone who can work in biotechnology. I want to be able to take students at early stages of their lives, and have them work in a biotech company to be exposed to the excitement of entrepreneurship. They can also then get the bug, and understand what it is and how you translate benefits for the community,” he said.

For more information on the Canadian Health Research Awards, please visit CIHR at www.cihr-irsc.gc.ca.

About the Canadian Institutes of Health Research
The Canadian Institutes of Health Research (CIHR) is the Government of Canada's agency for health research. CIHR's mission is to create new scientific knowledge and to catalyze its translation into improved health, more effective health services and products, and a strengthened Canadian health-care system. Composed of 13 Institutes, CIHR provides leadership and support to more than 11,000 health researchers and trainees across Canada.

About LifeSciences BC
LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, bioproducts, bioenergy and greater life sciences community of British Columbia through leadership, advocacy, active facilitation of investment and partnering, and promotion of our world-class science and industry. Our mission is to ensure British Columbia realizes its full potential to be a world leader in life sciences; generating a robust and sustainable bio-economy in British Columbia and Canada built on strong partnerships between industry, academia and government.

About the Centre for Molecular Medicine and Therapeutics

The CMMT is a synergistic group of scientists and researchers who share a strong sense of com
mitment to solve the many genetic questions surrounding human illness and well being.  Affiliated with the University of British Columbia and the Child & Family Research Institute, CMMT conducts discovery research and translates that research into effective clinical and therapeutic strategies to promote health. For more information, visit: http://www.cmmt.ubc.ca.

 

For more information please contact:
Barry Gee
Director, Operations and Communications
LifeSciences BC
Tel: (604) 602-5226
Email: bgee@lifesciencesbc.ca
www.lifesciencesbc.ca
 

Dr. Hayden Named Canada’s Health Researcher of the Year

LifeSciences BC is pleased to announce that one of British Columbia’s pre-eminent health researchers, Dr. Michael Hayden, Director and Senior Scientist at the Centre for Molecular Medicine and Therapeutics, and  University Killam Professor, Department of Medical Genetics at UBC has received the Canadian Institutes of Health Research’s (CIHR) Michael Smith Prize in Health Research:  Canada's Health Researcher of the Year award. Named in honor of the late Dr. Michael Smith, CIHR grants this prestigious award annually to a Canadian researcher in Biomedical and Clinical Research who has demonstrated outstanding commitment, innovation, creativity, achievement and leadership in health research.

“Clearly this is an accomplishment worthy of great celebration amongst our health research community and province as a whole,” commented Karimah Es Sabar, President, LifeSciences British Columbia.  “On behalf of this entire community, we applaud and thank Dr. Hayden for his outstanding work, and for bringing this recognition to BC. The contributions he has made to the health of patients while also the development of our biotech and life sciences industry here are immeasurable, thus extremely worthy of this honour, ” she noted.

British Columbia Minister of Health Services, the Honourable George Abbott added, “The late Dr. Michael Smith made British Columbia his home for more than 40 years, and left behind a great legacy as a scientist and humanitarian. I know all British Columbians will join me in congratulating Dr. Michael Hayden on receiving this award. We know that he and his team are building on this legacy, where world-class health research being conducted on Canada’s west coast is helping patients around the world.”

Throughout his career, Dr. Hayden has made major contributions to scientific excellence and to translating research findings into treatment approaches and services for patients.  Dr. Hayden nurtures a collaborative spirit and a supportive environment for investigators with varied expertise to work together towards a single mission:  building a healthier future. Dr. Hayden has also forged important linkages between researchers and industry, having founded multiple successful Canadian biotechnology companies in order to move research findings forward to therapeutic applications for the benefit of patients.  

As part of this distinction, Dr. Hayden will receive a research award of $500,000. During the next two years, he will use the award to support the operating costs for four new trainee awards in the areas of Global Health, Rare Diseases, Mental Health, and Biotechnology under the banner of Ripples of Hope. Dr. Hayden, a native of South Africa, has borrowed this term from a speech he attended when he was 15 years old, by Robert F. Kennedy in 1966 at the University of Cape Town. Dr. Hayden has already secured an additional $700,000 from a pharmaceutical partner that will go directly towards a related endowment, and he will continue working with the BC Children’s Hospital Foundation to raise additional funds to go directly towards this endowment or as annual trainee awards.

“Essentially what I’m hoping to do with these awards is create ripples of hope, that together with support from many others, will have impact against certain things we’re fighting against,” commented Dr. Hayden. “One such award will foster someone who can work in biotechnology. I want to be able to take students at early stages of their lives, and have them work in a biotech company to be exposed to the excitement of entrepreneurship. They can also then get the bug, and understand what it is and how you translate benefits for the community,” he said.

For more information on the Canadian Health Research Awards, please visit CIHR at www.cihr-irsc.gc.ca.

About the Canadian Institutes of Health Research
The Canadian Institutes of Health Research (CIHR) is the Government of Canada's agency for health research. CIHR's mission is to create new scientific knowledge and to catalyze its translation into improved health, more effective health services and products, and a strengthened Canadian health-care system. Composed of 13 Institutes, CIHR provides leadership and support to more than 11,000 health researchers and trainees across Canada.

About LifeSciences BC
LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, bioproducts, bioenergy and greater life sciences community of British Columbia through leadership, advocacy, active facilitation of investment and partnering, and promotion of our world-class science and industry. Our mission is to ensure British Columbia realizes its full potential to be a world leader in life sciences; generating a robust and sustainable bio-economy in British Columbia and Canada built on strong partnerships between industry, academia and government.

About the Centre for Molecular Medicine and Therapeutics

The CMMT is a synergistic group of scientists and researchers who share a strong sense of commitment to solve the many genetic questions surrounding human illness and well being.  Affiliated with the University of British Columbia and the Child & Family Research Institute, CMMT conducts discovery research and translates that research into effective clinical and therapeutic strategies to promote health. For more information, visit: http://www.cmmt.ubc.ca.

 

For more information please contact:
Barry Gee
Director, Operations and Communications
LifeSciences BC
Tel: (604) 602-5226
Email: bgee@lifesciencesbc.ca
www.lifesciencesbc.ca

Bariven S.A. Upgrades Venezuela's Airport De Guiria With Solar-Powered Aviation Lights From Carmanah Technologies

Carmanah Technologies Corporation (TSX: CMH) has received an order to supply solar-powered portable airfield lights for Bariven S.A. in Venezuela, a subsidiary of PDVSA. The order, valued at approximately $700,000, will provide the tools to equip Venezuela's Airport De Guiria with a stand-alone system of solar-powered LED (light emitting diode) aviation lights. Serving the Gulf of Paria, the Airport De Guiria offers convenient access for residents and visitors to this seaside community, while accommodating around-the-clock support and emergency response for local industrial enterprises including offshore oil developments within the region.

Cost effective, energy efficient, and easy to install, Airport De Guiria's new solar-powered lighting system includes Carmanah ICAO-compliant A704-5 runway edge lights, threshold lights, handheld radio controllers, A601 taxiway lights and supporting mounting hardware for permanent installation. Using the programmable interface, the user can set on/off times, brightness levels, flash patterns, infrared or visible outputs and more.

As the world's largest supplier of self-contained solar-powered LED airfield lighting technology, Carmanah provides a wide range of innovative and environmentally sustainable lighting solutions, field-proven to endure challenging environmental conditions including extreme temperatures, poor solar conditions, sandstorms, and flooding. With thousands of systems in operation, Carmanah provides the tools for a full range of airfield lighting and power applications, including permanent, portable, temporary and emergency lighting systems.

For more information on Carmanah solar-powered aviation lights, visit http://www.solarairportlights.com

 

About Carmanah Technologies Corporation

As one of most trusted names in solar technology, Carmanah has earned a reputation for delivering strong and effective products for industrial applications worldwide. Industry proven to perform reliably in some of the world's harshest environments, Carmanah's LED lights, LED edge-lit signs and stand-alone power systems provide a durable, dependable and cost effective energy alternative. Carmanah is a publicly traded company, with common shares listed on the Toronto Stock Exchange under the symbol "CMH." For more information, visit www.carmanah.com

 

Media Contact:

David Davies

Tel:  +1.250.382.4332

email: ddavies@carmanah.com

 

ICE Fund Backs Unique Biomass Technology

With support from the provincial government’s Innovative Clean Energy (ICE) Fund, Nexterra Energy Corp. is implementing an alternative energy system that will cut operating costs for a Lower Mainland industry and reduce greenhouse gas emissions by 22,000 tonnes per year, Technology, Trade and Economic Development Minister Ida Chong said today.

“The ICE Fund investment is realizing a double dividend in this project by helping an important local employer in New Westminster sustain good industry jobs and reduce costs, while lowering carbon emissions significantly,” said Chong. “This success showcases British Columbia as a clean technology leader – exactly what we expect the ICE Fund to accomplish.”

Nexterra Energy Corp., a successful B.C. cleantech company, will supply the Kruger Products Ltd. tissue mill in New Westminster with a direct fired biomass gasification system – the first of its kind in the pulp and paper industry. The system converts locally sourced wood residue into clean-burning syngas to fire a boiler to produce heat for the company’s industrial process – dramatically reducing the need to burn natural gas.

Jim Dangerfield of FPInnovations said advancements to Nexterra’s gasification technology make the switch from fossil fuels to syngas an attractive option for many of North America’s pulp and paper mills and other industrial site.

“Nexterra’s direct fired gasification system is a platform technology that can be used in many industrial applications,” Dangerfield said. “Replicating Nexterra’s technology at industrial sites in B.C. could result in an estimated 200,000 tonnes of greenhouse gas emission reductions in British Columbia annually by 2020.”

“Kruger Products’ new gasification system at its New Westminster mill clearly demonstrates its commitment to the environment and the sustainability of the community in which it operates,” said Nexterra president and CEO Jonathan Rhone. “Kruger, FPInnovations, the B.C. ICE Fund, Ethanol BC, and the federal government have been tremendous partners in this project, and we look forward to completing the plant later next year.”

Last July, the Province of British Columbia announced a $25-million investment in the first 15 successful ICE Fund applicants, including the Nexterra-Kruger project. The projects focused on bio-energy, solar, geothermal, biomass and other alternative energy approaches. The ICE Fund helps position British Columbia as a world leader in clean energy and fosters solutions to climate change.

In September 2008, the provincial government announced the ICE Fund will invest a further $25 million towards alternative energy projects in rural British Columbia communities. The ICE Fund will help B.C. cut greenhouse gas emissions by 33 per cent by 2020.

For more information on the Province’s Innovative Clean Energy (ICE) Fund, including details on community eligibility and application requirements, please visit the website at www.tted.gov.bc.ca/ICEFund/Pages/default.aspx.

Protox reports 2008 third quarter results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today released third quarter 2008 financial results for the three months ended September 30, 2008 ("2008 Q3").

"The third quarter marked significant advances for Protox, most prominently the early completion of patient enrolment in our Phase 2a study of PRX302 for the treatment of BPH," said Dr. Fahar Merchant, President and CEO of Protox. "We are very pleased with the 12 month data that we recently announced from our Phase 1 BPH study and look forward to releasing top line results from our Phase 2a BPH study before the end of the year."

 

2008 Q3 Highlights

 

    <<

       Completed enrolment of patients for Phase 2a study of PRX302 as a

        treatment for benign prostatic hyperplasia (BPH) one quarter ahead of

        schedule.

       Presented a poster entitled "Convection enhanced delivery (CED) of

        IL-4 pseudomonas exotoxin (PRX321): Increased distribution and MR

        monitoring" by Company collaborator Dr. Yael Mardor at the 8th

        Congress of the European Association of Neuro-oncology and received

        the EANO 2008 Poster Award.

       A PRX321 study conducted by Company collaborator Dr. Raj Puri and

        colleagues entitled "Potent in vitro and in vivo antitumor activity

        of interleukin-4-conjugated Pseudomonas exotoxin against human

        biliary tract carcinoma" was published in the International Journal

        of Cancer, Volume 123(12), p. 2915.

       Announced appointment of Dr. Jack Geltosky to the Board of Directors.

 

Subsequent Highlights

 

       Announced positive 12 month follow-up data from Phase 1 study of

        PRX302 in patients with BPH.

       Data from the PRX302 Phase 1 prostate cancer study was presented at

        the 15th Annual Scientific Retreat of the Prostate Cancer Foundation

        in Lake Tahoe, Nevada in October 2008. The poster presentation was

        entitled &q
uot;A Phase 1 Trial of PSA-Activated Pore-Forming Protoxin

        (PRX302) as Therapy for Locally Recurrent Prostate Cancer".

       Announced the expiry date for up to 9,948,507 share purchase warrants

        has been extended from November 29, 2008 to December 22, 2008.

    >>

 

FINANCIAL RESULTS

 

Protox has not earned any revenue in any of its previous fiscal years, other than income from interest earned on the Company's cash balances. During 2008 Q3 and the nine months ended September 30, 2008 ("2008 YTD") the Company earned interest income of $0.09 million and $0.23 million, respectively, compared to $0.06 million and $0.25 million for the corresponding 2007 comparative periods. The variance in interest income is a result of the investment products, interest rate and/or average cash balanced invested. Interest income is anticipated to continue to vary given the current and expected near term market environment.

 

The Company reported a net loss for 2008 Q3 of $2.5 million or $0.03 per share compared to $1.7 million or $0.03 per share for the three months ended September 30, 2007 comparative period ("2007 Q3"). The net loss for 2008 YTD totaled $6.4 million or $0.09 per share compared to $5.1 million or $0.09 per share for the nine months ended September 30, 2007 ("2007 YTD").

 

Research and development ("R&D") costs of nearly $2.0 million were incurred during 2008 Q3, as compared to $1.0 million incurred for the 2007 Q3 comparative period. For the 2008 YTD period, R&D costs totaled $4.6 million representing a $1.4 million (45%) increase from $3.2 million incurred during the 2007 YTD comparative period. The increase for both the 2008 Q3 and 2008

YTD periods reflects the continuing effect of the expanded scope and advancement of Protox's drug development and clinical trial activities.

 

Since the beginning of the year, incremental costs have been incurred for clinical and regulatory preparation activities. During the first three quarters of 2007, the scope and related cost of PRX321 CMC/drug supply manufacturing activities were significantly less while GBM Phase 2b clinical trial planning activities were nominal on a comparative basis. In addition, the early 2008 initiation of the PRX302 Phase 2a BPH study and enrolment completion during 2008 Q3 resulted in higher costs compared to 2007 YTD during which the predecessor Phase 1 study was initiated in mid 2007 Q2 and only partially enrolled by the end of 2007 Q3. A milestone payment relating to the PRX302 prostate cancer program also contributed to increased R&D costs earlier in 2008. Discovery research costs for 2008 Q3 were $0.2 million compared to $0.1 million for 2007 Q3, and increased roughly 50% from $0.4 million for 2007 YTD to $0.6 million for the 2008 YTD period. The increases in Discovery research costs reflect incremental spending associated with expanded CRADA and collaborative research activities for the Company's technology platforms.

 

General and administrative ("G&A") costs for 2008 Q3 declined 13% to $0.48 million from $0.55 million last quarter, however, increased 12% from $0.43 million incurred during the 2007 Q3 comparative period. YTD G&A costs have also increased at a similar rate to $1.57 million from $1.38 million for the 2007 YTD comparative period, although half of the increase is attributable to a one-time listing fee of $0.1 million incurred during 2008 Q1 when the Company graduated from the TSX Venture Exchange to the Toronto Stock Exchange. G&A costs will generally vary from period to period depending on the specific business development, market research and shareholder relations initiatives undertaken and related travel required at such time to support the Company's corporate objectives. The 2008 Q3 and 2008 YTD G&A costs increase is commensurate with the growth of the Company and its operations and also reflects an increase in business development personnel and activities.

 

During 2008 Q3 and 2008 YTD, the Company recorded nominal foreign exchange losses as the relative value of the U.S. and Canadian dollar changed marginally. However, during the 2007 Q3 and 2007 YTD comparative periods, $0.13 and $0.32 million of losses were recorded respectively with the majority representing unrealized losses on the Company's then more significant U.S. dollar reserves due to an approximate 15% relative decline in the value of the U.S. dollar during the first three quarters of 2007. The foreign exchange loss or gain recorded for a particular period and difference between comparative periods is a function of prevailing foreign exchange rates in effect at such time compared to the comparative period(s) as well as the amount of net financial assets or liabilities held or transacted during the subject periods.

 

At September 30, 2008, the Company had cash and cash equivalents of $9.8 million, a net decrease of $1.7 million from December 31, 2007. The Company had working capital of $8.5 million at September 30, 2008, a decrease of $1.2 million from the December 31, 2007.

 

As at November 11, 2008, the Company has 75,894,044 common shares issued and outstanding. In addition, the Company has 5,032,500 options outstanding to purchase common shares of the Company. Of the options currently outstanding, approximately 3.2 million are exercisable into an equivalent number of common shares of the Company at exercise prices ranging from $0.50 to $1.00 and with an average exercise price of $0.81. The Company also has warrants outstanding entitling warrant holders to purchase common shares as follows: i) 10,938,882 warrants
with an exercise price of $0.65 per common share and an expiry date of December 22, 2008 and ii) 584,413 warrants with an exercise price of $0.71 and expiry date of May 23, 2010.

 

For complete financial results, please see our filings at www.sedar.com.

 

About Protox

 

Protox Therapeutics is a leader in advancing novel, receptor targeted fusion proteins. Two novel drug candidates derived from the company's INxin(TM) and PORxin(TM) platforms are being developed in three clinical programs. A Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. Phase 2a clinical trials evaluating PRX302 (PORxin) for the treatment of localized prostate cancer and benign prostatic hyperplasia (enlarged prostate) are ongoing. Protox is also collaborating with the US National Institutes of

Health (NIH) on a research program focused on the discovery of next generation fully human targeted therapeutics.

 

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox' current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information: James Beesley, Director, Investor Relations, Protox Therapeutics, (604) 484-0975, jbeesley@protoxtherapeutics.com; Michael Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241, mmoore@equicomgroup.com

Illumina Selects GenoLogics as Next Generation Sequencing Lab & Data Management Partner

GenoLogics today announced that Geneus, their lab and data management system for genomics, was selected by Illumina to provide a combined solution offering with the Illumina sequencing platform, Genome Analyzer.

“We went to market to find a lab and data management partner that complemented our next generation sequencing platform in its ability to provide scalability, flexible workflow management, data pipelining capabilities, and an ability to support multiple applications, and the GenoLogics’ genomics solution, Geneus, proved to be an excellent fit,” said Omoshile Clement, Ph.D., Senior Product Manager of Informatics for Illumina. Dr. Clement continued, “The comprehensive way in which we are working with GenoLogics is a new approach for us, taking our partnership to a whole new level by integrating Genome Analyzer workflows into Geneus, in addition to integrating other Illumina platforms.”

The principles of the Illumina business partnership with GenoLogics include working on many initiatives across the company and making Illumina’s customers aware of the unique strengths of the Geneus solution. From a technology perspective, the partnership provides customers with a clear path to obtain an end-to-end lab and data management solution for next generation sequencing as well as a single system for enabling cross-genomics experiments.

“We are pleased that Illumina’s in-depth evaluations found Geneus to be a uniquely well suited genomics lab and data management solution for their Genome Analyzer,” said Michael Ball, CEO for GenoLogics. “Our partnership will provide clients with a single solution for genomics labs from sample submissions to results, no matter what type of research they are conducting from sequencing to microarray and real-time PCR platforms.”

Geneus supports Illumina’s Genome Analyzer and iScan data workflows for multiple genomics applications and provides genomics centers with an end-to-end solution from sample and workflow tracking to automating their bioinformatics pipelining and enabling reporting. Geneus is fully compatible with Illumina sequencing software components including GenomeStudio™.

Geneus is part of a broader suite of science-purposed informatics solution for discovery labs. Along with the GenoLogics product suite for biomedical informatics, Geneus enables research organizations to conduct translational research and other cross-science research efficiently and effectively.

Carmanah Q3 2008 Delivers Sustained Growth and Profitability

Victoria, BC, Canada (November 12, 2008) Carmanah Technologies Corporation (TSX:CMH) today announces its third quarter financial results for the three-month period ending September 2008.

In Q3 2008, Carmanah's recent strategic renewal and restructuring initiative proved especially timely, as the newly streamlined Company navigated challenging global market conditions to deliver its third profitable EBITDA quarter (adjusted for restructuring charge) in a row. While supporting the restructuring initiatives announced in June, the Company introduced a new flagship product to its line of solar LED marine lanterns, entered into a partnership with wireless technology provider ENCOM, and reported significant sales wins in key target markets including aviation lights for airfields in the Middle East and solar power systems for telecommunication towers throughout North Africa.

Highlights for the Quarter

  • Sales results: $13.9 million down $1.6 million from the same period in 2007, although sales are 4.7% higher when the Q4 2007 sale of the home power business is factored in
  • Gross margin up: 37.7% for 2008, up from 30.5% in 2007
  • Operating costs reduced: $4.6 million (excluding restructuring costs) down from $5.3 million for the same period of 2007 – restructuring charge of $0.5 million during the three month period ended September 30, 2008, compared to nil for the same period of 2007
  • Improved bottom line: Net income of $0.8 million, up from a net loss of $0.8 million in the same period of 2007
  • Higher Adjusted EBITDA: Adjusted EBITDA of $1.5 million, up from negative $0.8 million in the same period of 2007
  • Positive cash flow from operations: $0.2 million, compared to $1.5 million for the same period in 2007, which was due to a one-time reduction of surplus inventory
  • Cash balance increased: $5.5 million, up from $1.4 million in the same period of 2007
  • Nil debt: Continued debt-free operation

Summary of Results

The third quarter of 2008 saw continued progress towards Carmanah's renewed corporate objectives announced at the start of the year, including the ongoing implementation of the major restructuring initiatives introduced in Q2 to support the Company's return to sustained, profitable growth.

According to Ted Lattimore, Carmanah CEO, this renewed focus on the Company's core strengths, combined with a commitment to maximizing efficiency and controlling costs, has helped prepare the Company to weather the recent global economic conditions. "Even in today's challenging times, we can now see how our broad based restructuring last quarter has resulted in our increased strength today," said Lattimore. "With the majority of our transition behind us, Carmanah is now prepared to face the challenges ahead as a much leaner, more focused and responsive business. I am confident that our team has the focus, commitment and skill to persevere, and that the current rocky markets will merely test and clarify our strategy. Even with the challenges of today's stock market, our operating costs remain low, we have cash in the bank, and we're maintaining an overall financial position that is increasingly enviable these days. The key over the coming months will be to keep sales coming, and with our strong industrial markets, our new global sales team and some exciting new products, we're well prepared to do just that."

Carmanah CFO, Roland Sartorius added, "…our recent efforts to control costs and support sustained, profitable growth could not have come at a bet
ter time. Guided by solid business metrics, our net cash balance has grown from a 2007 low of negative $2 million to more than $5 million as at Q3 2008. We've maintained our positive growth trend — with no bank debt — and recorded our third quarter of positive Adjusted EBITDA and cash flow results in a row," said Sartorius. "Thanks to our loyal customer base, our relevant technology, and an unfaltering commitment to sustainable growth and solid business fundamentals, we believe that Carmanah is in good financial shape for whatever challenges lay ahead — even in today's changeable economic environment."

For full financial statements as well as the Management Discussion & Analysis, visit:

http://www.carmanah.com/content/investors/ShowNewsRelease.aspx?id=081112pt

 

Media Contact:

David  Davies

ddavies@carmanah.com

direct:   250.382.4332

 

Two Out Of Three Florida Top Principals Use Victoria-based Etraffic's SnapShot Data Analysis Tool for School Improvement

The finalists for the 6th Annual Leonard Miller Principal Leadership Award, hosted by the Council for Educational Change, were announced on October 31st, 2008. Two of the three finalists actively use Etraffic's Student Performance SnapShot data analysis tool to help raise student achievement levels.
 
The finalists were chosen from state-wide applicants in Florida who demonstrated extraordinary leadership in a Council program(s) in these three criteria: raised student achievement; empowered staff leadership; and formed meaningful partnerships.
 
Dr. Rosann Sidener from Miami-Dade Public Schools raised Miami Beach High's school grade from a D to a B. Terry Strong, Winston EL, Polk County Schools raised the school grade from C to B to A, with 81% of the student population on free and reduced lunch programs.  Both utilize the SnapShot data analysis tool.
 
"The impact that data analysis has on student improvement is profound, as evidenced by the success of these two finalist Principals," says John Juricic, partner with Etraffic Solutions. "SnapShot gets valuable information to educators quickly so that they can concentrate on what they do best: teaching. A teacher's work with their students is what really counts. By making it easier for administrators and teachers to comprehend student achievement data, we hope to make their job easier and to positively impact student performance at their school."
 
SnapShot takes key data that schools collect on their students, such as test scores and demographics, analyses it, and presents it in an easy to comprehend format. By simplifying data analysis, teachers and administrators are able to make the best use of their time and maximize their impact on student performance and school improvement.
 
"Etraffic would like to congratulate all of the finalists and wish them the best of luck on November 19th when the winner will be announced." says Juricic.
 
The Award was initiated in 2002 to honour Leonard Miller's legacy. He was Chair of the Florida Annenberg Challenge, Council founder, noted philanthropist and founder of Lennar Corp. Based on the results of the Challenge evaluation, Principal leadership was identified as the catalyst to increase student achievement and it is the basis of the Council's work and the Award.
 
About the Council for Educational Change
The Council is a state-wide 501(C)(3) educational improvement organization, successor to the $100 million South Florida Annenberg Challenge Initiative. Its mission is Leading the Way to Better Education–developing business and education partnerships; preparing and empowering school leaders; and using lessons learned through research to address critical education issues.
 
About Etraffic Solutions Inc.
Etraffic Solutions is one of North America's leading e-learning solutions providers, providing products and services to the education industry and a variety of corporate clients. Delivering education and training materials on virtually any platform and in any format, Etraffic Solutions has proven expertise at delivering online and print learning in a variety of languages localized to specific cultures.
 
For more information on Student Performance SnapShot visit the website at www.studentperformance.com or contact:
 
Robert Bailey
robert@etrafficsolutions.com
1 866 658 8238 ext. 33